DRIO
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
DarioHealth Corp.
- Nom
- DarioHealth Corp.
- Secteur
- Healthcare
- Industrie
- Medical - Specialties
- Bourse
- NASDAQ
- Capitalisation
- $33.3M
- Employés
- 163
- PDG
- Erez Raphael
- Site web
- https://www.dariohealth.com
- Marché
- ABSIAVNSFLGTINNVMYGNNNNN
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 14430 titres (~100000 USD)
- Insiders
- Matheis Dennis
- Total bought
-
$100,000
Avg buy (VWAP, 90d window) $6.93 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-23
- Last synced
-
2026-10-19 22:33:27
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-23 | Matheis Dennis | Buy · P | 14,430 | $6.93 | $100,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-03 Drivers: fundamentals. Moteurs : fondamentaux.
DRIO presents a genuine near-term event-driven setup — a Fortune 50 contract win, new insurer deal, GLP-1 program launch, and insider cluster buying all converge ahead of Q2 earnings on Aug 11, yielding a credible…
The first sentence of the analysis written for DRIO on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 3.73 · operating margin -164% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 56.6% | 49.1% | 29.4% | 34.9% | 39.3% | |
| Ebit Margin | -171.1% | -164.6% | -291.7% | -218.1% | -363.1% | |
| Ebitda Margin | -157.0% | -137.1% | -267.2% | -201.0% | -341.3% | |
| Operating Profit Margin | -163.9% | -213.6% | -276.1% | -205.4% | -372.9% | |
| Pretax Profit Margin | -186.1% | -164.9% | -291.7% | -224.9% | -374.1% | |
| Continuous Operations Profit Margin | -186.6% | -158.1% | -292.0% | -224.9% | -374.2% | |
| Net Profit Margin | -186.6% | -158.1% | -292.0% | -224.9% | -374.2% | |
| Bottom Line Profit Margin | -180.3% | -111.3% | -269.6% | -230.8% | -329.2% | |
| Current Ratio | 3.734 | 2.436 | 3.789 | 3.386 | 3.172 | |
| Quick Ratio | 3.271 | 2.151 | 3.383 | 2.975 | 2.739 | |
| Solvency Ratio | -0.915 | -0.754 | -1.424 | -1.467 | -4.750 | |
| Cash Ratio | 2.815 | 1.669 | 2.945 | 2.551 | 2.504 | |
| Price To Earnings Ratio | -14.049 | -21.243 | -17.824 | -32.548 | -56.026 | |
| Price To Earnings Growth Ratio | -1.485 | 0.345 | 0.670 | 0.753 | 3.380 | |
| Forward Price To Earnings Growth Ratio | -1.485 | 0.345 | 0.670 | 0.753 | 3.380 | |
| Price To Earnings Diluted Ratio | -14.049 | -21.243 | -17.824 | -32.548 | -56.026 | |
| Price To Earnings Diluted Growth Ratio | -1.485 | 0.345 | 0.670 | 0.753 | 3.380 | |
| Price To Book Ratio | 8.315 | 8.822 | 16.786 | 25.290 | 50.309 | |
| Price To Sales Ratio | 25.261 | 23.497 | 47.956 | 73.154 | 209.813 | |
| Price To Free Cash Flow Ratio | -21.654 | -16.418 | -31.521 | -41.785 | -84.940 | |
| Price To Operating Cash Flow Ratio | -21.772 | -16.476 | -32.127 | -42.286 | -85.379 | |
| Debt To Assets Ratio | 0.288 | 0.254 | 0.306 | 0.235 | 0.003 | |
| Debt To Equity Ratio | 0.467 | 0.419 | 0.508 | 0.351 | 0.003 | |
| Debt To Capital Ratio | 0.319 | 0.295 | 0.337 | 0.260 | 0.003 | |
| Long Term Debt To Capital Ratio | 0.312 | 0.246 | 0.297 | 0.185 | 0.000 | |
| Financial Leverage Ratio | 1.621 | 1.651 | 1.658 | 1.490 | 1.178 | |
| Working Capital Turnover Ratio | 0.906 | 0.921 | 0.502 | 0.715 | 0.703 | |
| Operating Cash Flow Ratio | -2.782 | -2.318 | -2.432 | -2.473 | -3.506 | |
| Operating Cash Flow Sales Ratio | -1.160 | -1.426 | -1.493 | -1.730 | -2.457 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.004 | 1.019 | 1.012 | 1.005 | |
| Debt Service Coverage Ratio | -9.295 | -6.350 | -11.838 | -4.832 | -200.140 | |
| Interest Coverage Ratio | -10.912 | -601.500 | -87.115 | -21.174 | -910.643 | |
| Short Term Operating Cash Flow Coverage Ratio | -60.328 | -7.074 | -7.683 | -5.423 | -189.508 | |
| Operating Cash Flow Coverage Ratio | -0.817 | -1.277 | -1.028 | -1.706 | -175.641 | |
| Capital Expenditure Coverage Ratio | -182.683 | -279.435 | -52.019 | -83.499 | -193.138 | |
| Dividend Paid And Capex Coverage Ratio | -182.683 | -279.435 | -52.019 | -83.499 | -193.138 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -16.242 | -17.202 | -17.815 | -36.007 | -60.959 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 56.6% | ▲7.6% | ▲14.8% |
| Ebit Margin | -171.1% | ▼-6.5% | ▲70.6% |
| Ebitda Margin | -157.0% | ▼-19.9% | ▲63.7% |
| Operating Profit Margin | -163.9% | ▲49.6% | ▲82.4% |
| Pretax Profit Margin | -186.1% | ▼-21.2% | ▲62.2% |
| Continuous Operations Profit Margin | -186.6% | ▼-28.5% | ▲60.6% |
| Net Profit Margin | -186.6% | ▼-28.5% | ▲60.6% |
| Bottom Line Profit Margin | -180.3% | ▼-69.0% | ▲43.9% |
| Current Ratio | 3.734 | ▲1.297 | ▲0.430 |
| Quick Ratio | 3.271 | ▲1.120 | ▲0.367 |
| Solvency Ratio | -0.915 | ▼-0.162 | ▲0.947 |
| Cash Ratio | 2.815 | ▲1.146 | ▲0.318 |
| Price To Earnings Ratio | -14.049 | ▲7.194 | ▲14.289 |
| Price To Earnings Growth Ratio | -1.485 | ▼-1.830 | ▼-2.218 |
| Forward Price To Earnings Growth Ratio | -1.485 | ▼-1.830 | ▼-2.218 |
| Price To Earnings Diluted Ratio | -14.049 | ▲7.194 | ▲14.289 |
| Price To Earnings Diluted Growth Ratio | -1.485 | ▼-1.830 | ▼-2.218 |
| Price To Book Ratio | 8.315 | ▼-0.507 | ▼-13.589 |
| Price To Sales Ratio | 25.261 | ▲1.763 | ▼-50.676 |
| Price To Free Cash Flow Ratio | -21.654 | ▼-5.236 | ▲17.610 |
| Price To Operating Cash Flow Ratio | -21.773 | ▼-5.296 | ▲17.836 |
| Debt To Assets Ratio | 0.288 | ▲0.035 | ▲0.071 |
| Debt To Equity Ratio | 0.467 | ▲0.048 | ▲0.118 |
| Debt To Capital Ratio | 0.319 | ▲0.023 | ▲0.076 |
| Long Term Debt To Capital Ratio | 0.312 | ▲0.066 | ▲0.104 |
| Financial Leverage Ratio | 1.621 | ▼-0.030 | ▲0.101 |
| Working Capital Turnover Ratio | 0.906 | ▼-0.015 | ▲0.156 |
| Operating Cash Flow Ratio | -2.783 | ▼-0.464 | ▼-0.080 |
| Operating Cash Flow Sales Ratio | -1.160 | ▲0.266 | ▲0.493 |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | ▲0.002 | ▼-0.004 |
| Debt Service Coverage Ratio | -9.294 | ▼-2.944 | ▲37.196 |
| Interest Coverage Ratio | -10.912 | ▲590.587 | ▲315.356 |
| Short Term Operating Cash Flow Coverage Ratio | -60.328 | ▼-53.254 | ▼-6.325 |
| Operating Cash Flow Coverage Ratio | -0.817 | ▲0.460 | ▲35.277 |
| Capital Expenditure Coverage Ratio | -182.683 | ▲96.752 | ▼-24.528 |
| Dividend Paid And Capex Coverage Ratio | -182.683 | ▲96.752 | ▼-24.528 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -16.242 | ▲0.960 | ▲13.403 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $564.8M | $635.4M | $976.0M | $2.02B | $4.30B | |
| Enterprise value | $570.3M | $637.8M | $968.7M | $2.00B | $4.27B | |
| EV / Sales | 25.51x | 23.59x | 47.60x | 72.38x | 208.07x | |
| EV / Op. cash flow | -21.98x | -16.54x | -31.89x | -41.84x | -84.67x | |
| EV / Free cash flow | -21.86x | -16.48x | -31.29x | -41.34x | -84.23x | |
| EV / EBITDA | -16.24x | -17.20x | -17.82x | -36.01x | -60.96x | |
| Net debt / EBITDA | -0.16x | -0.07x | 0.13x | 0.38x | 0.51x | |
| Current ratio | 3.73x | 2.44x | 3.79x | 3.39x | 3.17x | |
| Income quality | 0.62x | 0.90x | 0.51x | 0.77x | 0.66x | |
| Graham net-net | -$0 | -$0 | $0 | $1 | $2 | |
| Tax burden | 100.3% | 95.8% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 108.8% | 100.2% | 100.0% | 103.1% | 103.0% | |
| Working capital | $25.5M | $23.9M | $34.8M | $46.2M | $31.2M | |
| Invested capital | $100.1M | $101.9M | $83.7M | $99.7M | $86.3M | |
| Return on assets | -37.9% | -36.0% | -61.7% | -52.2% | -76.2% | |
| Operating ROA | -32.0% | -53.6% | -52.1% | -51.7% | -112.3% | |
| Return on tangible assets | -113.6% | -100.1% | -120.4% | -92.0% | -164.5% | |
| Return on equity | -61.4% | -59.4% | -102.2% | -77.7% | -89.7% | |
| Return on invested capital | -36.2% | -51.1% | -63.9% | -52.1% | -88.3% | |
| Return on capital employed | -36.4% | -56.5% | -67.0% | -56.9% | -88.5% | |
| Earnings yield | -7.4% | -6.7% | -6.1% | -3.1% | -1.8% | |
| Free cash flow yield | -4.6% | -6.1% | -3.2% | -2.4% | -1.2% | |
| Capex / Op. cash flow | -0.5% | -0.4% | -1.9% | -1.2% | -0.5% | |
| Capex / Depreciation | 4.5% | 1.9% | 11.7% | 12.1% | 5.9% | |
| Capex / Sales | 0.6% | 0.5% | 2.9% | 2.1% | 1.3% | |
| SG&A / Sales | 158.9% | 173.2% | 205.4% | 169.3% | 304.0% | |
| R&D / Sales | 61.7% | 89.4% | 99.5% | 71.0% | 83.9% | |
| Stock comp / Sales | 41.9% | 58.4% | 96.8% | 61.4% | 121.7% | |
| Intangibles / Total assets | 66.6% | 64.1% | 48.8% | 43.3% | 53.7% | |
| Days sales outstanding | 44d | 72d | 65d | 85d | 32d | |
| Days payables outstanding | 110d | 81d | 29d | 47d | 150d | |
| Operating cycle | 206d | 198d | 194d | 246d | 214d | |
| Cash conversion cycle | 96d | 118d | 165d | 199d | 65d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-11.1%EV / Sales ▲+8.1%EV / EBITDA ▲+5.6%EV / Op. cash flow ▼-5.445Earnings yield ▼-0.007
Profitability
Return on equity ▼-0.021Return on assets ▼-0.019Return on invested capital ▲+0.149Return on capital employed ▲+0.201Operating ROA ▲+0.216Income quality ▼-0.280Tax burden ▲+0.044
Efficiency
Days sales outstanding ▼-28.641Days payables outstanding ▲+29.550Operating cycle ▲+7.906Cash conversion cycle ▼-21.644Capex / Sales ▲+0.001R&D / Sales ▼-0.277
Balance-sheet strength
Current ratio ▲+1.297Net debt / EBITDA ▼-0.091Working capital ▲+1592000.000Invested capital ▼-1747000.000Intangibles / Total assets ▲+0.026
Change over 5 years
Valuation
Market cap ▼-86.9%EV / Sales ▼-87.7%EV / EBITDA ▲+73.4%EV / Op. cash flow ▲+62.686Earnings yield ▼-0.056
Profitability
Return on equity ▲+0.283Return on assets ▲+0.383Return on invested capital ▲+0.520Return on capital employed ▲+0.522Operating ROA ▲+0.803Income quality ▼-0.035Tax burden ▲+0.002
Efficiency
Days sales outstanding ▲+11.823Days payables outstanding ▼-39.609Operating cycle ▼-8.346Cash conversion cycle ▲+31.263Capex / Sales ▼-0.006R&D / Sales ▼-0.223
Balance-sheet strength
Current ratio ▲+0.561Net debt / EBITDA ▼-0.667Working capital ▼-5743000.000Invested capital ▲+13792000.000Intangibles / Total assets ▲+0.130
Employee count
Peer market caps
Recent news
- 2026-10-06 DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs A component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-users Evaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life population Aon estimates an additional 1.6 to 2.8 percentage points of potential healthcare cost savings as a result of providing direct access to physicians while simultaneously managing multiple chronic conditions, for potential total of 10% annual savings Independent analysis finds that evidence supports the economic value of Dario''s multi-condition digital health platform for payers including employers, health plans, health systems and accountable care organizations (ACOs) NEW YORK, Oct. 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the results of a review titled "An Independent Review of Evidence Supporting DarioHealth''s Clinical and Cost-Savings Impact" conducted by the Managed Care Services Team of Aon plc ("Aon"), a leading global professional services firm. Based upon its review of data provided by Dario and published studies identified by Dario, Aon''s Managed Care Services Team concluded that the evidence reviewed supports an estimated reduction in total healthcare costs of 2.5% to 7.2% annually across a covered population – measured against total healthcare spend, not only the spend of program participants.
- 2026-09-17 Dario Wins Contract with One of New Jersey''s Largest Health Plans Representing 1.5 Million Covered Lives Agreement secured through channel partner Amwell significantly expands Dario''s reach through its channel distribution strategy Program for Dario''s cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027 Marks the third large state health plan signed through Amwell in the past 12 months, following contracts in Arizona and Florida NEW YORK, Sept. 17, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives.
- 2026-09-10 DarioHealth (NASDAQ:DRIO) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened DarioHealth Corp. (NASDAQ: DRIO - Get Free Report)''s share price crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $7.74 and traded as low as $6.80. DarioHealth shares last traded at $6.82, with a volume of 6,322 shares changing hands. Wall Street
- 2026-08-31 Pro Medicus (OTCMKTS:PMCUF) versus DarioHealth (NASDAQ:DRIO) Head to Head Survey Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Analyst Ratings This is a summary of recent ratings
- 2026-08-25 Contrasting DarioHealth (NASDAQ:DRIO) and Phreesia (NYSE:PHR) Phreesia (NYSE: PHR - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional and Insider Ownership 92.1% of Phreesia shares are
- 2026-08-11 DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
- 2026-08-11 DarioHealth Q2 Earnings Call Highlights DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business.
- 2026-08-11 DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.
- 2026-08-11 DarioHealth Reports Second Quarter 2026 Financial Results Second quarter 2026 revenue was $5.2 million, reflecting the Company''s strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition Commercial momentum with three significant wins in recent weeks, led by a top-5 national health plan expansion with the potential to approximately triple Dario''s potential revenue opportunity — its third such expansion — plus a 5th Fortune 50 client and a new health insurer via the Amwell channel Expanded into provider-backed clinical care delivery, accessing a larger portion of the healthcare value chain and increasing the potential revenue opportunity per client Pro forma cash of $36.8 million following $22.8 million net proceeds from at-the-market registered direct financing with participation from existing long-term shareholders and new fundamental institutional investors completed in July 2026 Conference call today, August 11, 2026 at 8:30 am ET NEW YORK, Aug. 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the second quarter ended June 30, 2026. "We believe that Dario has reached an important stage where the investments made in our technology, product, and distribution infrastructure are compounding positive momentum," said Erez Raphael, Chief Executive Officer of Dario.
- 2026-08-04 Dario Expands Provider-Backed Cardiometabolic Platform with New Women''s Health and Sleep Solutions Aligning with Client Demand New programs, expected to begin revenue contribution Q4 2026, extend Dario''s integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company''s provider-backed care strategy AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario''s participation in reimbursement-driven healthcare services NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed healthcare providers.